USP22 transcriptional activity is negatively regulated by the histone deacetylase inhibitor trichostatin A
Related Experiment Video
Updated: Apr 22, 2026

Repressing Gene Transcription by Redirecting Cellular Machinery with Chemical Epigenetic Modifiers
Published on: September 20, 2018
Jianjun Xiong1, Xiaoyuan Xu1, Xiaou Zhou1
1Jiangxi Province Key Laboratory of Systems Biomedicine, Jiujiang University, Jiujiang, Jiangxi 332000, P.R. China.
Abstract:
The ubiquitin‑specific protease 22 (USP22) gene is overexpressed in the majority of types of cancer cells, and has been implicated in tumorigenesis. However, the mechanisms that regulate its expression remain unclear. The results of the present study demonstrated that the expression of USP22 is negatively regulated by trichostatin A (TSA), a classical histone deacetylase inhibitor. Furthermore, TSA was revealed to interfere with the binding of RNA polymerase II to the USP22 promoter, directly suppressing its transcription. In addition, the overexpression of USP22 was observed to attenuate TSA‑induced apoptosis in HeLa cells. To the best of our knowledge, these results provide the first insight into the regulation of the USP22 gene by antitumor drugs and into the mechanisms underlying the anticancer activity of TSA.
Insights
Trichostatin A (TSA) inhibits USP22 gene expression by blocking transcription, a key mechanism in its anticancer activity. Overexpressing USP22 reduces TSA-induced apoptosis, revealing new insights into cancer drug regulation.
Area of Science:
- Molecular Biology
- Cancer Research
- Epigenetics
Background:
- The ubiquitin-specific protease 22 (USP22) gene is frequently overexpressed in various cancers and linked to tumorigenesis.
- Mechanisms regulating USP22 expression, particularly in response to therapeutic agents, are not well understood.
Purpose of the Study:
- To investigate the regulatory effects of trichostatin A (TSA) on USP22 gene expression.
- To elucidate the molecular mechanisms by which TSA influences USP22 transcription and its role in cancer cell apoptosis.
Main Methods:
- Utilized histone deacetylase inhibitor TSA to treat cancer cells.
- Assessed USP22 gene expression levels and transcriptional activity.
- Investigated the interaction between RNA polymerase II and the USP22 promoter.
- Examined the impact of USP22 overexpression on TSA-induced apoptosis in HeLa cells.
Main Results:
- TSA negatively regulates USP22 gene expression.
- TSA inhibits USP22 transcription by preventing RNA polymerase II binding to the USP22 promoter.
- Overexpression of USP22 diminishes TSA-mediated apoptosis in HeLa cells.
Conclusions:
- This study provides the first evidence of USP22 gene regulation by an antitumor drug (TSA).
- The findings reveal that TSA suppresses USP22 transcription, contributing to its anticancer effects.
- USP22 plays a role in modulating apoptosis induced by TSA, offering potential therapeutic targets.
More Related Videos
11:32Identification of Transcription Factor Regulators using Medium-Throughput Screening of Arrayed Libraries and a Dual-Luciferase-Based Reporter
Published on: March 27, 2020
10:44In Vitro Selection of Engineered Transcriptional Repressors for Targeted Epigenetic Silencing
Published on: May 5, 2023
Related Concept Videos
Co-activators and Co-repressors
Eukaryotic Transcription Inhibitors
Eukaryotic transcription inhibitors usually contain two distinct domains, a...
Transcription Attenuation in Prokaryotes
There are several different mechanisms used to attenuate transcription. In ribosome mediated...
Master Transcription Regulators
Master Transcription Regulators
RNA Polymerase II Accessory Proteins